Lymphoma Clinical Trials & Research

Lymphoma Clinical Trials & Research

Share
Print
Share
Print

Our mission at MSK has always been to care for and cure people with cancer. As part of this goal, we’ve worked for decades to find new treatments. Many of our innovations and approaches have set the standard for care.

The MSK Lymphoma Service has one of the largest and most innovative clinical trial programs in the world. We offer a diverse range of treatment options for patients with Hodgkin and non-Hodgkin lymphoma. Because of our active clinical trial research program, we have helped to develop most of the lymphoma drugs that have improved patient outcomes and are currently FDA approved. Many of our clinical trials turn the latest discoveries from the laboratory into new treatments for patients with lymphoma.

Choosing MSK may give you access to new treatment options that are not yet readily available and could turn out to be tomorrow’s cures. We have extensive experience in matching patients with the clinical trials that will benefit them the most.


Burkitt’s Lymphoma
Chronic Lymphocytic Lymphoma (CLL)
Diffuse Large B-Cell Lymphoma

Newly Diagnosed/Frontline Studies and Advanced Disease

Prior Treatment (Relapsed/Refractory)

A Phase I Study of Abexinostat and Ibrutinib to Treat Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 19-080]

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
Andrew D. Zelenetz
[Protocol 16-1614]

A Phase I Study of REGN3767 and/or REGN2810 Immunotherapy in Patients with Advanced Lymphoma
M. Lia Palomba
[Protocol 17-421]

A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Erel Joffe
[Protocol 18-053]

A Phase I Study of AZD5991 in Patients with Recurrent or Persistent Multiple Myeloma
Neha S. Korde
[Protocol 18-117]

A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Erel Joffe
[Protocol 19-151]

A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]

A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297]

A Phase III Study of Polatuzumab Vedotin Combined with Rituximab, Gemcitabine, and Oxaliplatin in People with Diffuse Large B-Cell Lymphoma
Matthew J. Matasar
[Protocol 20-031]

Follicular Lymphoma
HIV+ Lymphoma

Newly Diagnosed/Frontline Studies and Advanced Disease

AIDS Malignancy Consortium 101: A Pilot Study to Assess Adding Ibrutinib to Standard R-EPOCH Treatment for AIDS-Related Lymphomas
Ariela Noy
[Protocol 17-543]

Prior Treatment (Relapsed/Refractory)

A Phase I Study of Nivolumab and Ipilimumab Immunotherapy for Advanced HIV-Related Solid Tumors, including Hodgkin Lymphoma
Mark A. Dickson
[Protocol 16-1286]

non-therapeutic

Hodgkin Lymphoma
Mantle Cell Lymphoma

Newly Diagnosed/Frontline Studies and Advanced Disease

A Phase II Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
Andrew D. Zelenetz
[Protocol 18-427]

A Phase III Study of Ibrutinib Alone or with Venetoclax in Patients with Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 18-157]

Prior Treatment (Relapsed/Refractory)

A Phase I Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Recurrent or Persistent Mantle Cell Lymphoma
Anita Kumar
[Protocol 17-216]

A Phase I Study of Abexinostat and Ibrutinib to Treat Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 19-080]

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
Andrew D. Zelenetz
[Protocol 16-1614]

A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Erel Joffe
[Protocol 18-053]

A Phase III Study of Ibrutinib Alone or with Venetoclax in Patients with Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 18-157]

A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Erel Joffe
[Protocol 19-151]

A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]

A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297]

non-therapeutic

Marginal Zone Lymphoma
Mediastinal Grey Zone Lymphoma

Newly Diagnosed/Frontline Studies and Advanced Disease

Prior Treatment (Relapsed/Refractory)

A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297]

A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]

Small Lymphocytic Lymphoma (SLL)
T-cell Lymphoma: PTCL, CTCL and Extranodal NK nasal type
Waldenstrom’s Macroglobulinemia